Foster Dykema Cabot & Partners LLC Has $818,000 Stock Position in Danaher Co. (NYSE:DHR)

Foster Dykema Cabot & Partners LLC raised its holdings in shares of Danaher Co. (NYSE:DHR) by 30.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,561 shares of the conglomerate’s stock after buying an additional 836 shares during the quarter. Foster Dykema Cabot & Partners LLC’s holdings in Danaher were worth $818,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Osterweis Capital Management Inc. raised its stake in Danaher by 2.1% during the 4th quarter. Osterweis Capital Management Inc. now owns 102,041 shares of the conglomerate’s stock valued at $23,424,000 after purchasing an additional 2,105 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of Danaher by 7.8% during the 4th quarter. NewEdge Advisors LLC now owns 56,790 shares of the conglomerate’s stock worth $13,036,000 after purchasing an additional 4,129 shares during the period. Ceredex Value Advisors LLC raised its position in shares of Danaher by 29.8% during the fourth quarter. Ceredex Value Advisors LLC now owns 223,073 shares of the conglomerate’s stock valued at $51,206,000 after buying an additional 51,150 shares during the last quarter. Stenger Family Office LLC bought a new stake in shares of Danaher in the fourth quarter valued at about $281,000. Finally, Finward Bancorp acquired a new stake in Danaher during the fourth quarter worth about $230,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

Shares of NYSE:DHR opened at $190.85 on Thursday. The business has a fifty day moving average of $202.61 and a 200-day moving average of $228.47. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. Danaher Co. has a twelve month low of $171.00 and a twelve month high of $281.70. The firm has a market cap of $136.40 billion, a PE ratio of 36.15, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the firm posted $2.09 earnings per share. On average, equities research analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a yield of 0.67%. Danaher’s dividend payout ratio is currently 24.24%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $277.00 price target (down previously from $299.00) on shares of Danaher in a report on Thursday, January 30th. Raymond James reaffirmed a “market perform” rating on shares of Danaher in a research report on Monday, February 3rd. JPMorgan Chase & Co. lowered their price target on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Jefferies Financial Group dropped their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research note on Wednesday, January 29th. Finally, Stifel Nicolaus upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 target price on the stock in a research report on Friday, March 14th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $274.81.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.